Featured Prescription Drugs Resources
This slideshow looks at past, present and future trends in prescription drug spending with a focus on the role of specialty drugs.
Slideshow See More
Related Prescription Drugs Resources
- Kaiser Health News Coverage of Prescription Drug Issues
- How Does the Trump Administration Drug Pricing Blueprint Affect Medicaid?
- Medicare Part D in 2018: The Latest on Enrollment, Premiums, and Cost Sharing
- Snapshots of Recent State Initiatives in Medicaid Prescription Drug Cost Control
- Summary of Recent and Proposed Changes to Medicare Prescription Drug Coverage and Reimbursement
- Kaiser Health Tracking Poll – March 2018: Views on Prescription Drug Pricing and Medicare-for-all Proposals
- 10 Essential Facts About Medicare and Prescription Drug Spending
- No Limit: Medicare Part D Enrollees Exposed to High Out-of-Pocket Drug Costs Without a Hard Cap on Spending
- Public Opinion on the Use and Abuse of Prescription Opioids
- Searching for Savings in Medicare Drug Price Negotiations
- Medicaid’s Most Costly Outpatient Drugs
- Retail Prescription Drugs Filled at Pharmacies (Annual per Capita)
This slideshow draws on recent Kaiser Family Foundation poll findings to provide an in-depth look at the public’s attitudes toward prescription drugs and their prices. Results include Americans’ opinions on drug affordability, pharmaceutical companies, and various potential measures that could lower prices.
Slideshow See More
- view as grid
- view as list
Kaiser Health Tracking Poll – Late Summer 2018: The Election, Pre-Existing Conditions, and Surprises on Medical Bills
The latest Kaiser Health Tracking Poll continues to find pre-existing conditions as a widespread concern with most Americans saying it is very important that the Affordable Care Act’s (ACA) protections for people with pre-existing conditions remain law. With health care costs continuing to be a major topic in the 2018 campaigns, the poll looks at the public’s experiences with unexpected medical bills and finds that this tops a list of possible problems people could face. In addition, the poll examines the public’s views of President Trump’s contentious relationship with prescription drug companies.
Poll: The ACA’s Pre-Existing Condition Protections Remain Popular with the Public, including Republicans, As Legal Challenge Looms This Week
Public Not Confident in President Trump’s Calls on Drug Companies to Lower Prices As a federal court considers a challenge to the Affordable Care Act’s constitutionality, the public, including most Republicans, wants protections for people with pre-existing conditions preserved, the latest Kaiser Family Foundation tracking poll finds. Large majorities of…
This data note examines the latest data and trends in the Medicare Part D coverage gap, where enrollees must pay a greater share of their prescription drug costs. The note includes data about how many Part D enrollees reached the coverage gap, their average out-of-pocket spending, the value of manufacturer discounts, and recent and proposed changes affecting out-of-pocket costs for Part D enrollees who reach the gap.
Poll: Two-thirds of Voters Say a Candidate’s Position on Pre-existing Conditions is Important to their Vote, More than Say the Same about Drug Costs, ACA Repeal or Medicare-for-All
About two-thirds (65%) of voters say a candidate’s support for continued protections for people with pre-existing health conditions is either the “single most important factor” or “very important” to their vote in the upcoming midterms elections, finds the latest Kaiser Family Foundation tracking poll. That’s a larger share than says the…
Kaiser Health Tracking Poll – June 2018: Campaigns, Pre-Existing Conditions, and Prescription Drug Ads
The June 2018 KFF Tracking Poll examines the top issues voters want to hear candidates talk about during their 2018 congressional campaigns, including the importance of specific health care positions such as continuing protections for people with pre-existing conditions. The Kaiser poll also examines the public’s views and experiences with prescription drug advertisements and pricing.
What’s in the Administration’s 5-Part Plan for Medicare Part D and What Would it Mean for Beneficiaries and Program Savings?
With rising concern over increases in prescription drug costs, the Trump Administration has proposed what it calls a “5-part plan” that would change several features of the Medicare Part D drug benefit. This brief describes the Administration’s five Part D proposals and discusses the potential implications for people with Part D prescription drug coverage and Medicare program spending, based on estimates from the Congressional Budget Office.
This issue brief examines how the Trump Administration proposals to lower drug costs described in the Administration’s Blueprint affect Medicaid. These include proposals to change the Medicaid Drug Rebate Program, as well as other approaches.
Three firms Account for Over Half of All Medicare Part D Enrollees in 2018, and Pending Mergers Would Further Consolidate the Marketplace
In 2018, three Medicare Part D plan sponsors—UnitedHealth, Humana, and CVS Health—account for more than half of the program’s 43 million Part D enrollees (55%) and two-thirds of all stand-alone drug plan enrollees, indicating a marketplace that is dominated by a handful of major insurers, according to a new Kaiser…
This brief about the 2018 Medicare Part D marketplace analyzes the latest data on Medicare drug coverage and trends over time, including both stand-alone prescription drug plans and Medicare Advantage drug plans. The analysis focuses on enrollment, premiums, cost sharing, and the low-income subsidy.